George J. Kahaly
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
George J. Kahaly has a total of 374 co-authors. Here are the top co-authors by number of shared publications:
Tanja Diana
Molecular Thyroid Research Laboratory, Department of Medicine I, Johannes Gutenberg University (JGU) Medical Center, Mainz, Germany
14 shared publicationsLara Frommer
Molecular Thyroid Research Laboratory, Department of Medicine I , Johannes Gutenberg University (JGU) Medical Center , Mainz , Germany
10 shared publicationsJochem König
Institute of Medical Biostatistics, Epidemiology and Informatics , Johannes Gutenberg University (JGU) Medical Center , Mainz , Germany
9 shared publicationsJan Wolf
Molecular Thyroid Research Laboratory, Department of Medicine I, Johannes Gutenberg-University (JGU) Medical Center
8 shared publicationsMaximilian Luffy
Molecular Thyroid Research Laboratory, Department of Medicine I, Johannes Gutenberg-University (JGU) Medical Center
7 shared publicationsT. Diana
Molecular Thyroid Research Laboratory, Department of Medicine I, Johannes Gutenberg University Medical Center, Langenbeckstreet 1, 55131, Mainz, Germany
7 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1920590
The dual IGF-1R/IR blocker, Linsitinib, modulates human orbital fibroblast activity and proliferation
Aim: The insulin-like growth factor-1 receptor (IGF-1R) and its downstream signaling pathways drive proliferation, survival, and extracellular matrix production, representing key therapeutic targets in thyroid eye disease (TED). This novel in vitro study investigated the inhibitory effects of the dual IGF-1R/insulin receptor small-molecule inhibitor Linsitinib on orbital target cell activity, proliferation, and survival. Methods: Human orbital fibroblasts (OF) were pre-treated with increasing doses of Linsitinib and stimulated with 100 ng/mL IGF-1 to quantify hyaluronic acid (HA) and pro-collagen in supernatants via ELISA. Intracellular protein kinase B (AKT) phosphorylation at Serine 473 was quantified in cell lysates. Additionally, an equimolar comparison between Linsitinib and the anti-IGF-1R monoclonal antibody Teprotumumab was performed in IGF-1R-expressing cells. Proliferation was assessed both microscopically and by tetrazolium assay, while apoptosis was evaluated by caspase-3/7 activity. Results: Linsitinib markedly suppressed IGF-1-induced HA and pro-collagen secretion, with TED OF showing significantly greater sensitivity and exclusive morphological evidence of apoptosis compared to control OF. Linsitinib effectively inhibited IGF-1-induced AKT phosphorylation to baseline levels in OF. Equimolar comparison in IGF-1R-expressing cells demonstrated that Linsitinib outperformed Teprotumumab in inhibiting cell proliferation across most tested concentrations, whereas Teprotumumab showed higher potency only at the lowest concentrations. While Teprotumumab failed to induce cell death, Linsitinib triggered robust activity of the apoptosis markers caspase-3/7. Morphologically, in contrast to Teprotumumab, Linsitinib induced dose-dependent changes characterized by cellular contraction and formation of gaps in the monolayer. Conclusion: Linsitinib reverses OF activation through intracellular kinase blockade while outperforming Teprotumumab in equimolar comparison. These findings highlight the role of Linsitinib as a potent, dual-targeted therapy for TED.
- 2 October 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1920590
Open AccessThe dual IGF-1R/IR blocker, Linsitinib, modulates human orbital fibroblast activity and proliferation
Aim: The insulin-like growth factor-1 receptor (IGF-1R) and its downstream signaling pathways drive proliferation, survival, and extracellular matrix production, representing key therapeutic targets in thyroid eye disease (TED). This novel in vitro study investigated the inhibitory effects of the dual IGF-1R/insulin receptor small-molecule inhibitor Linsitinib on orbital target cell activity, proliferation, and survival. Methods: Human orbital fibroblasts (OF) were pre-treated with increasing doses of Linsitinib and stimulated with 100 ng/mL IGF-1 to quantify hyaluronic acid (HA) and pro-collagen in supernatants via ELISA. Intracellular protein kinase B (AKT) phosphorylation at Serine 473 was quantified in cell lysates. Additionally, an equimolar comparison between Linsitinib and the anti-IGF-1R monoclonal antibody Teprotumumab was performed in IGF-1R-expressing cells. Proliferation was assessed both microscopically and by tetrazolium assay, while apoptosis was evaluated by caspase-3/7 activity. Results: Linsitinib markedly suppressed IGF-1-induced HA and pro-collagen secretion, with TED OF showing significantly greater sensitivity and exclusive morphological evidence of apoptosis compared to control OF. Linsitinib effectively inhibited IGF-1-induced AKT phosphorylation to baseline levels in OF. Equimolar comparison in IGF-1R-expressing cells demonstrated that Linsitinib outperformed Teprotumumab in inhibiting cell proliferation across most tested concentrations, whereas Teprotumumab showed higher potency only at the lowest concentrations. While Teprotumumab failed to induce cell death, Linsitinib triggered robust activity of the apoptosis markers caspase-3/7. Morphologically, in contrast to Teprotumumab, Linsitinib induced dose-dependent changes characterized by cellular contraction and formation of gaps in the monolayer. Conclusion: Linsitinib reverses OF activation through intracellular kinase blockade while outperforming Teprotumumab in equimolar comparison. These findings highlight the role of Linsitinib as a potent, dual-targeted therapy for TED.
- Open Access
- 9 December 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (5) , 1248-1257
Secukinumab in Moderate-to-Severe Graves Orbitopathy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
Context: Interleukin (IL)-17, a key proinflammatory cytokine, drives inflammation and fibrosis in Graves orbitopathy (GO), and elevated IL-17 and Th17 cells correlate with disease activity and severity. Objective: The ORBIT study aimed to evaluate the efficacy and safety of secukinumab, an IL-17A inhibitor, in individuals with active, moderate-to-severe GO. Methods: A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial was conducted. Adults with active, moderate-to-severe, non-sight–threatening GO randomly (1:1) received secukinumab 300 mg or placebo subcutaneously over a 16-week double-blind treatment period, followed by an additional 16-week open-label treatment phase for proptosis nonresponders. Safety parameters, thyroid-related hormones, and autoantibodies were also assessed. The primary end point was overall response of reduced Clinical Activity Score (CAS) of 2 or more points and a reduction of 2 mm or greater in proptosis from baseline without worsening in the fellow eye at week 16. Results: Twenty-eight adult GO patients with a CAS of 4 or greater were enrolled (secukinumab, n = 14; placebo, n = 14). None in either the secukinumab or placebo group achieved an overall response at weeks 16 and 32, respectively, when all patients received open-label secukinumab. No clinically meaningful changes were observed in ophthalmic symptoms and signs, proptosis, lid aperture, eye muscle motility, CAS, and health-related quality of life either at week 16 or week 32. No meaningful effect on serum levels of thyroid-related hormones and antibodies was observed. Secukinumab was well tolerated, with mostly mild adverse events. Neither treatment-induced study discontinuation nor new safety signals were registered. Conclusion: Secukinumab did not show clinical efficacy vs placebo when treating patients with active, moderate-to-severe GO.
- 9 December 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (5) , 1248-1257
Open AccessSecukinumab in Moderate-to-Severe Graves Orbitopathy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
Context: Interleukin (IL)-17, a key proinflammatory cytokine, drives inflammation and fibrosis in Graves orbitopathy (GO), and elevated IL-17 and Th17 cells correlate with disease activity and severity. Objective: The ORBIT study aimed to evaluate the efficacy and safety of secukinumab, an IL-17A inhibitor, in individuals with active, moderate-to-severe GO. Methods: A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial was conducted. Adults with active, moderate-to-severe, non-sight–threatening GO randomly (1:1) received secukinumab 300 mg or placebo subcutaneously over a 16-week double-blind treatment period, followed by an additional 16-week open-label treatment phase for proptosis nonresponders. Safety parameters, thyroid-related hormones, and autoantibodies were also assessed. The primary end point was overall response of reduced Clinical Activity Score (CAS) of 2 or more points and a reduction of 2 mm or greater in proptosis from baseline without worsening in the fellow eye at week 16. Results: Twenty-eight adult GO patients with a CAS of 4 or greater were enrolled (secukinumab, n = 14; placebo, n = 14). None in either the secukinumab or placebo group achieved an overall response at weeks 16 and 32, respectively, when all patients received open-label secukinumab. No clinically meaningful changes were observed in ophthalmic symptoms and signs, proptosis, lid aperture, eye muscle motility, CAS, and health-related quality of life either at week 16 or week 32. No meaningful effect on serum levels of thyroid-related hormones and antibodies was observed. Secukinumab was well tolerated, with mostly mild adverse events. Neither treatment-induced study discontinuation nor new safety signals were registered. Conclusion: Secukinumab did not show clinical efficacy vs placebo when treating patients with active, moderate-to-severe GO.
- Open Access
- 1 December 2025
- Published by Bioscientifica in European Thyroid Journal
- Vol. 14 (6)
Comparison of the 2021 EUGOGO guidelines and the 2022 ATA/ETA consensus statement for the management of Graves’ orbitopathy
Background: In 2021, the European Group on Graves’ orbitopathy (EUGOGO) published clinical practice guidelines for the management of GO, and in 2022, the American and European Thyroid Associations published the ATA/ETA consensus statement on the same topic. Aims: i) To highlight similarities and differences between the two documents, ii) to suggest possible amendments for future revisions. Results and conclusions: The two documents show a high degree of concordance as to classification, assessment, and prevention, as well as treatment of mild GO, moderate-to-severe and inactive GO, and sight-threatening GO. The major disagreement regards treatment of moderate-to-severe and active GO. The EUGOGO guidelines, written when teprotumumab was not available outside the USA, indicate intravenous glucocorticoids (IVGC) (with/without mycophenolate) as the first-line treatment, whereas the ATA/ETA consensus statement indicates teprotumumab as the first-line treatment for virtually all phenotypes of moderate-to-severe and active GO, particularly when exophthalmos is predominant. However, also in the ATA/ETA consensus statement, IVGC are the preferred treatment when the goal is GO inactivation and resolution of inflammation, and among the preferred treatments (in combination with orbital radiotherapy) when the goals are inactivation and correction of eye dysmotility. Recent developments to be considered in future revisions of the guidelines/consensus statement include the possible use of biologicals (teprotumumab and tocilizumab) for dysthyroid optic neuropathy, treatment of longstanding inactive GO with teprotumumab, reconsideration of the cautious use of radioactive iodine in patients with moderate-to-severe and active GO concomitantly treated with IVGC (with/without orbital radiotherapy), and use of statins as an adjunct therapy.
- 1 December 2025
- Published by Bioscientifica in European Thyroid Journal
- Vol. 14 (6)
Open AccessComparison of the 2021 EUGOGO guidelines and the 2022 ATA/ETA consensus statement for the management of Graves’ orbitopathy
Background: In 2021, the European Group on Graves’ orbitopathy (EUGOGO) published clinical practice guidelines for the management of GO, and in 2022, the American and European Thyroid Associations published the ATA/ETA consensus statement on the same topic. Aims: i) To highlight similarities and differences between the two documents, ii) to suggest possible amendments for future revisions. Results and conclusions: The two documents show a high degree of concordance as to classification, assessment, and prevention, as well as treatment of mild GO, moderate-to-severe and inactive GO, and sight-threatening GO. The major disagreement regards treatment of moderate-to-severe and active GO. The EUGOGO guidelines, written when teprotumumab was not available outside the USA, indicate intravenous glucocorticoids (IVGC) (with/without mycophenolate) as the first-line treatment, whereas the ATA/ETA consensus statement indicates teprotumumab as the first-line treatment for virtually all phenotypes of moderate-to-severe and active GO, particularly when exophthalmos is predominant. However, also in the ATA/ETA consensus statement, IVGC are the preferred treatment when the goal is GO inactivation and resolution of inflammation, and among the preferred treatments (in combination with orbital radiotherapy) when the goals are inactivation and correction of eye dysmotility. Recent developments to be considered in future revisions of the guidelines/consensus statement include the possible use of biologicals (teprotumumab and tocilizumab) for dysthyroid optic neuropathy, treatment of longstanding inactive GO with teprotumumab, reconsideration of the cautious use of radioactive iodine in patients with moderate-to-severe and active GO concomitantly treated with IVGC (with/without orbital radiotherapy), and use of statins as an adjunct therapy.
- Open Access
- 29 November 2025
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (1) , e70119
Type 1 Diabetes and Other Autoimmune Diseases—Epidemiology, Pathophysiology and Screening
Introduction: The interplay between type 1 diabetes (T1D) and concomitant autoimmune diseases (AID) is both clinically and scientifically relevant. In this review, we delineate the epidemiological, pathophysiological and practical aspects underlying polyautoimmunity with a focus on T1D. Method: A comprehensive review of literature on T1D and associated AID was conducted, with the aim of drawing informed conclusions relevant to clinical practice. It draws on a targeted PubMed search conducted March–May 2025, emphasising recent peer‐reviewed articles in English. Results: Epidemiological data consistently indicate that individuals with T1D exhibit a significantly increased prevalence of additional AID. Familial aggregation of discordant AID and the concept of polyglandular autoimmune syndromes (PAS) or autoimmune polyendocrinopathy highlight that multiple AID can cluster and occur in a sequential and overlapping fashion, with T1D frequently acting as either an early or a subsequent manifestation. Thereby, genetic susceptibility, environmental triggers and epigenetic factors are pivotal in the initiation and progression of autoimmunity. Clinically, the coexistence of T1D with other AID poses significant challenges in disease management, often necessitating adjustments in therapeutic regimens and careful monitoring to mitigate complications. Early detection via stratified autoantibody testing is important for timely intervention and improved long‐term outcomes. Conclusions: Accordingly, screening for T1D‐associated autoantibodies in individuals with a personal or family history of AIDs, and vice versa, should be implemented in clinical practice.
- 29 November 2025
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (1) , e70119
Open AccessType 1 Diabetes and Other Autoimmune Diseases—Epidemiology, Pathophysiology and Screening
Introduction: The interplay between type 1 diabetes (T1D) and concomitant autoimmune diseases (AID) is both clinically and scientifically relevant. In this review, we delineate the epidemiological, pathophysiological and practical aspects underlying polyautoimmunity with a focus on T1D. Method: A comprehensive review of literature on T1D and associated AID was conducted, with the aim of drawing informed conclusions relevant to clinical practice. It draws on a targeted PubMed search conducted March–May 2025, emphasising recent peer‐reviewed articles in English. Results: Epidemiological data consistently indicate that individuals with T1D exhibit a significantly increased prevalence of additional AID. Familial aggregation of discordant AID and the concept of polyglandular autoimmune syndromes (PAS) or autoimmune polyendocrinopathy highlight that multiple AID can cluster and occur in a sequential and overlapping fashion, with T1D frequently acting as either an early or a subsequent manifestation. Thereby, genetic susceptibility, environmental triggers and epigenetic factors are pivotal in the initiation and progression of autoimmunity. Clinically, the coexistence of T1D with other AID poses significant challenges in disease management, often necessitating adjustments in therapeutic regimens and careful monitoring to mitigate complications. Early detection via stratified autoantibody testing is important for timely intervention and improved long‐term outcomes. Conclusions: Accordingly, screening for T1D‐associated autoantibodies in individuals with a personal or family history of AIDs, and vice versa, should be implemented in clinical practice.
- Open Access
- 1 October 2025
- Published by Bioscientifica in European Thyroid Journal
- Vol. 14 (5)
Graves’ disease in ectopic thyroid tissue: a scoping review and a case study
Background: Persistent Graves’ disease (GD) after total thyroidectomy is sporadic and may be explained by incomplete total thyroidectomy, GD in ectopic thyroid tissue (ETT) or struma ovarii. Methods: We present a novel case of ectopic GD in a giant paracardiac mass, including an in-depth histologic exam. We searched the PubMed database on GD in ETT. Results: A 34-year-old woman presented with severe thyrotoxicosis, 4 months after total thyroidectomy, and 6 weeks after cessation of levothyroxine substitution. Persistently high thyrotropin receptor antibodies (TSH-R-Ab) (27 IU/L, normal: 5,000 μg/L (normal: <77 μg/L) suggested GD in ETT. A 99mTc-pertechnetate SPECT/CT scan showed uptake in a paracardiac mass. After surgical removal of the 13 cm paracardiac mass, euthyroidism was achieved. Histology was typically remarkable for a Graves’ pattern in the ETT, as opposed to a nodular pattern in the eutopic thyroid. The additional scoping review encompasses 29 reported ETT cases, of which only 11 were in the mediastinum. Graves’ eye disease was present in 11/29 subjects. Conclusion: This is the first report showing a markedly different histology between the thyroid and the ectopic tissue. Persistent systemic severe GD post-thyroidectomy led to the detection of a giant paracardiac ectopic thyroid. GD in ETT is rare and presents a diagnostic challenge.
- 1 October 2025
- Published by Bioscientifica in European Thyroid Journal
- Vol. 14 (5)
Open AccessGraves’ disease in ectopic thyroid tissue: a scoping review and a case study
Background: Persistent Graves’ disease (GD) after total thyroidectomy is sporadic and may be explained by incomplete total thyroidectomy, GD in ectopic thyroid tissue (ETT) or struma ovarii. Methods: We present a novel case of ectopic GD in a giant paracardiac mass, including an in-depth histologic exam. We searched the PubMed database on GD in ETT. Results: A 34-year-old woman presented with severe thyrotoxicosis, 4 months after total thyroidectomy, and 6 weeks after cessation of levothyroxine substitution. Persistently high thyrotropin receptor antibodies (TSH-R-Ab) (27 IU/L, normal: 5,000 μg/L (normal: <77 μg/L) suggested GD in ETT. A 99mTc-pertechnetate SPECT/CT scan showed uptake in a paracardiac mass. After surgical removal of the 13 cm paracardiac mass, euthyroidism was achieved. Histology was typically remarkable for a Graves’ pattern in the ETT, as opposed to a nodular pattern in the eutopic thyroid. The additional scoping review encompasses 29 reported ETT cases, of which only 11 were in the mediastinum. Graves’ eye disease was present in 11/29 subjects. Conclusion: This is the first report showing a markedly different histology between the thyroid and the ectopic tissue. Persistent systemic severe GD post-thyroidectomy led to the detection of a giant paracardiac ectopic thyroid. GD in ETT is rare and presents a diagnostic challenge.
- Open Access
- 4 September 2025
- Published by Bioscientifica in European Thyroid Journal
- Vol. 14 (5)
Unravelling the pathogenic mechanisms in Graves’ orbitopathy
Graves’ orbitopathy (GO) is characterized by orbital inflammatory infiltration, expansion of orbital tissues due to de novo adipogenesis and over-production of hydrophilic glycosaminoglycans, as well as myofibroblastic differentiation resulting in tissue fibrosis. Thyrotropin receptor antibody (TSH-R-Ab) is the major stimulus, which activates thyrotropin receptor (TSH-R)/insulin-like growth factor-1 receptor (IGF-1R) and its downstream signalling in orbital fibroblasts (OF). Clinical evaluation of TSH-R-Ab, the specific biomarker of Graves’ disease (GD) and the associated orbitopathy, provides important clinical information concerning diagnosis, disease monitoring and prognosis of GO. TSH-R/IGF-1R crosstalk represents the principal mechanism of activation of OF, the key effector cells in GO. T cells and monocytes/macrophages predominate in the inflammatory infiltrates and B-T cell co-stimulation results in mutual activation. Mast cell-derived products also activate OF. In the presence of various pro-inflammatory molecules, activated OF and lymphocytes perpetuate orbital inflammation and mediate tissue remodelling. Enhanced oxidative stress drives various pathological processes in GO and many antioxidant agents have shown inhibitory effects on OF. Highly differential gene and protein expression exists between GO and normal subjects, as well as between active/severe and inactive/mild GO, providing important insights into the disease mechanisms. The lack of confirmed genetic susceptibility to GO development suggests that epigenetic mechanisms (e.g. DNA methylation and microRNAs) may play a role in regulating gene and protein expression, and hence disease phenotypes. The gut microbiome differs significantly between GO patients and healthy individuals. Modifying gut microbiota in GO animal models improves GO. Emerging evidence indicates that hypercholesterolaemia is associated with increased risk of developing GO, while statin use is a protective factor.
- 4 September 2025
- Published by Bioscientifica in European Thyroid Journal
- Vol. 14 (5)
Open AccessUnravelling the pathogenic mechanisms in Graves’ orbitopathy
Graves’ orbitopathy (GO) is characterized by orbital inflammatory infiltration, expansion of orbital tissues due to de novo adipogenesis and over-production of hydrophilic glycosaminoglycans, as well as myofibroblastic differentiation resulting in tissue fibrosis. Thyrotropin receptor antibody (TSH-R-Ab) is the major stimulus, which activates thyrotropin receptor (TSH-R)/insulin-like growth factor-1 receptor (IGF-1R) and its downstream signalling in orbital fibroblasts (OF). Clinical evaluation of TSH-R-Ab, the specific biomarker of Graves’ disease (GD) and the associated orbitopathy, provides important clinical information concerning diagnosis, disease monitoring and prognosis of GO. TSH-R/IGF-1R crosstalk represents the principal mechanism of activation of OF, the key effector cells in GO. T cells and monocytes/macrophages predominate in the inflammatory infiltrates and B-T cell co-stimulation results in mutual activation. Mast cell-derived products also activate OF. In the presence of various pro-inflammatory molecules, activated OF and lymphocytes perpetuate orbital inflammation and mediate tissue remodelling. Enhanced oxidative stress drives various pathological processes in GO and many antioxidant agents have shown inhibitory effects on OF. Highly differential gene and protein expression exists between GO and normal subjects, as well as between active/severe and inactive/mild GO, providing important insights into the disease mechanisms. The lack of confirmed genetic susceptibility to GO development suggests that epigenetic mechanisms (e.g. DNA methylation and microRNAs) may play a role in regulating gene and protein expression, and hence disease phenotypes. The gut microbiome differs significantly between GO patients and healthy individuals. Modifying gut microbiota in GO animal models improves GO. Emerging evidence indicates that hypercholesterolaemia is associated with increased risk of developing GO, while statin use is a protective factor.
- 29 August 2025
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 49 (1) , 33-45
Bibliometrics in thyroid eye disease
Purpose Thyroid Eye Disease (TED) is the most common thyroid-related autoimmune inflammatory disorder. Despite a surge in TED-related publications over the past five years—matching the total output of the preceding sixteen years—a systematic bibliometric analysis remains absent. This study aims to systematically map the knowledge structure, research hotspots, and future trends in TED research. Methods Publications related to TED from 2004 to 2024 were retrieved from the Web of Science Core Collection database. VOSviewer, CiteSpace, and the R package “Bibliometrix” were utilized for bibliometric analysis. Results A total of 4,306 publications from 91 countries, led by the United States and China, were included. The number of TED publications has shown a consistent upward trend. The leading research institution was the University of Pisa. Among scientific journals, the Journal of Clinical Endocrinology & Metabolism, THYROID, Journal of Endocrinological Investigation, and Ophthalmic Plastic and Reconstructive Surgery, had the highest number of publications. The 15,766 contributing authors were led by Smith, Kahaly, Marino, Yoon, and Marcocci in terms of publication volume. Bartalena was identified as the most frequently co-cited author. TED research focuses foremost on mechanisms (pathogenesis, immunity, autoantibodies), treatment (management, therapy, orbital complications), and epidemiology (prevalence, diagnosis, risk factors). Artificial intelligence, disease activity, hearing loss, teprotumumab, dysthyroid optic neuropathy, inflammation, and magnetic resonance imaging are the primary keywords of emerging research hotspots. Conclusion Our study represents the first comprehensive bibliometric analysis of TED, summarizing its knowledge mapping, research hotspots, and frontiers, while providing valuable insights for scholars in the field.
- 29 August 2025
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 49 (1) , 33-45
Bibliometrics in thyroid eye disease
Purpose Thyroid Eye Disease (TED) is the most common thyroid-related autoimmune inflammatory disorder. Despite a surge in TED-related publications over the past five years—matching the total output of the preceding sixteen years—a systematic bibliometric analysis remains absent. This study aims to systematically map the knowledge structure, research hotspots, and future trends in TED research. Methods Publications related to TED from 2004 to 2024 were retrieved from the Web of Science Core Collection database. VOSviewer, CiteSpace, and the R package “Bibliometrix” were utilized for bibliometric analysis. Results A total of 4,306 publications from 91 countries, led by the United States and China, were included. The number of TED publications has shown a consistent upward trend. The leading research institution was the University of Pisa. Among scientific journals, the Journal of Clinical Endocrinology & Metabolism, THYROID, Journal of Endocrinological Investigation, and Ophthalmic Plastic and Reconstructive Surgery, had the highest number of publications. The 15,766 contributing authors were led by Smith, Kahaly, Marino, Yoon, and Marcocci in terms of publication volume. Bartalena was identified as the most frequently co-cited author. TED research focuses foremost on mechanisms (pathogenesis, immunity, autoantibodies), treatment (management, therapy, orbital complications), and epidemiology (prevalence, diagnosis, risk factors). Artificial intelligence, disease activity, hearing loss, teprotumumab, dysthyroid optic neuropathy, inflammation, and magnetic resonance imaging are the primary keywords of emerging research hotspots. Conclusion Our study represents the first comprehensive bibliometric analysis of TED, summarizing its knowledge mapping, research hotspots, and frontiers, while providing valuable insights for scholars in the field.
- 16 June 2025
- Published by The Endocrine Society in Endocrine Reviews
- Vol. 46 (5) , 709-735
Stress and Thyroid Function—From Bench to Bedside
Experimental animal and human studies illustrate the effect of various stress forms on the thyroid gland and the regulation of thyroid hormones (THs) through the thyrotropic multiloop control circuit. The hypothalamic–pituitary–thyroid axis (HPT) axis is part of the physiological stress system and mediates key regulators of metabolic activity during stress response. Genetically characterized individuals are more affected in their response to stressors, and their psychological response is extremely amplified. This leads to significant increases in TH serum levels as soon as a negative stressor appears. Physical stressors are used to induce psychological stress (eg, physical exercise, starvation, sleep deprivation, hypoxia, and cold temperatures), all of which impact thyroid function. In addition, somatic illnesses may also affect the thyroid gland or may be related to a thyroidal dysfunction. As a psychosocial stressor in animal models, neonatal separation from the mother was used, affecting energy homeostasis and causing an increase in thyroliberin (TRH) expression in female rats and an increase in TRH degrading ectoenzyme in male rats. In mice with restrained stress, THs are important mediators of accelerated tumor growth. In human studies, isolated sexual abuse in childhood doubles the risk of thyroid dysfunction, with puerperal depression after sexual abuse in childhood increasing the risk for HPT axis disorders and elevated thyroid autoantibodies 4-fold. In addition, psychological illnesses influence thyroid function. In the future, laboratory studies with standardized induction of various stress forms are warranted to better understand stress-induced effects on the HPT axis and their corresponding mechanisms.
- 16 June 2025
- Published by The Endocrine Society in Endocrine Reviews
- Vol. 46 (5) , 709-735
Stress and Thyroid Function—From Bench to Bedside
Experimental animal and human studies illustrate the effect of various stress forms on the thyroid gland and the regulation of thyroid hormones (THs) through the thyrotropic multiloop control circuit. The hypothalamic–pituitary–thyroid axis (HPT) axis is part of the physiological stress system and mediates key regulators of metabolic activity during stress response. Genetically characterized individuals are more affected in their response to stressors, and their psychological response is extremely amplified. This leads to significant increases in TH serum levels as soon as a negative stressor appears. Physical stressors are used to induce psychological stress (eg, physical exercise, starvation, sleep deprivation, hypoxia, and cold temperatures), all of which impact thyroid function. In addition, somatic illnesses may also affect the thyroid gland or may be related to a thyroidal dysfunction. As a psychosocial stressor in animal models, neonatal separation from the mother was used, affecting energy homeostasis and causing an increase in thyroliberin (TRH) expression in female rats and an increase in TRH degrading ectoenzyme in male rats. In mice with restrained stress, THs are important mediators of accelerated tumor growth. In human studies, isolated sexual abuse in childhood doubles the risk of thyroid dysfunction, with puerperal depression after sexual abuse in childhood increasing the risk for HPT axis disorders and elevated thyroid autoantibodies 4-fold. In addition, psychological illnesses influence thyroid function. In the future, laboratory studies with standardized induction of various stress forms are warranted to better understand stress-induced effects on the HPT axis and their corresponding mechanisms.
- 21 May 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (1) , 199-208
High-Throughput Proteomics and Immunohistochemistry of Orbital Connective Tissue in Graves' Orbitopathy
Context: High-throughput proteomics (HTP) helps identify characteristic signaling networks specific to certain diseases, thus offering a range of potential applications in basic research and precision medicine. Immunohistochemistry can uncover local orbital immunity. Objective: To investigate key proteins linked to the progression of Graves' orbitopathy (GO). Methods: Thirty-one orbital connective tissue samples from patients with GO (11 with clinically severe and 12 with mild GO), and from 8 control subjects were examined using HTP. We focused on the intersection of differentially expressed proteins (DEPs) that differ between severe GO and both mild GO and control. Gene ontology and the Kyoto Encyclopedia of Genes and Genomes were used to analyze DEPs. Immunohistochemical verification was performed using 11 severe and 7 mild GO orbital tissues. Immunostaining was quantitatively analyzed using reliable and automated software that ensures objective, operator-independent evaluation. Results: A total of 4579 proteins were identified: 847, 790, and 208 DEPs were registered when comparing mild GO vs control, severe GO vs control, and severe vs mild GO, respectively (all P < .05). Using a cutoff threshold of fold change ≥2.0 during screening, 5 significantly upregulated DEPs (Latent-transforming growth factor β-binding protein 2, Lysyl oxidase homolog, Ras-interacting protein 1, Integrin beta 3, Coagulation factor XII) overlapped between severe GO and both mild GO and control, while 163 upregulated DEPs were involved in various biological processes (angiogenesis, inflammation, tissue remodeling, and fibrosis). Subsequent immunohistochemical tissue validation confirmed the HTP findings. Conclusion: For the first time, combined proteomics and immunohistochemistry detected upregulated orbital tissue proteins potentially implicated in GO progression.
- 21 May 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (1) , 199-208
High-Throughput Proteomics and Immunohistochemistry of Orbital Connective Tissue in Graves' Orbitopathy
Context: High-throughput proteomics (HTP) helps identify characteristic signaling networks specific to certain diseases, thus offering a range of potential applications in basic research and precision medicine. Immunohistochemistry can uncover local orbital immunity. Objective: To investigate key proteins linked to the progression of Graves' orbitopathy (GO). Methods: Thirty-one orbital connective tissue samples from patients with GO (11 with clinically severe and 12 with mild GO), and from 8 control subjects were examined using HTP. We focused on the intersection of differentially expressed proteins (DEPs) that differ between severe GO and both mild GO and control. Gene ontology and the Kyoto Encyclopedia of Genes and Genomes were used to analyze DEPs. Immunohistochemical verification was performed using 11 severe and 7 mild GO orbital tissues. Immunostaining was quantitatively analyzed using reliable and automated software that ensures objective, operator-independent evaluation. Results: A total of 4579 proteins were identified: 847, 790, and 208 DEPs were registered when comparing mild GO vs control, severe GO vs control, and severe vs mild GO, respectively (all P < .05). Using a cutoff threshold of fold change ≥2.0 during screening, 5 significantly upregulated DEPs (Latent-transforming growth factor β-binding protein 2, Lysyl oxidase homolog, Ras-interacting protein 1, Integrin beta 3, Coagulation factor XII) overlapped between severe GO and both mild GO and control, while 163 upregulated DEPs were involved in various biological processes (angiogenesis, inflammation, tissue remodeling, and fibrosis). Subsequent immunohistochemical tissue validation confirmed the HTP findings. Conclusion: For the first time, combined proteomics and immunohistochemistry detected upregulated orbital tissue proteins potentially implicated in GO progression.
- Open Access
- 20 May 2025
- Published by Springer Nature in Thyroid Research
- Vol. 18 (1) , 1-15
Hypothyroidism: playing the cardiometabolic risk concerto
Background: Thyroid hormones influence the function of essentially every system of the body, including the cardiovascular and metabolic system. Thyroid hormone replacement with levothyroxine (LT4) is the mainstay of pharmacological management for people with (especially clinically overt) hypothyroidism, and it is important to ensure the cardiovascular and metabolic safety of this treatment. This is especially so as in hypothyroidism, cardiometabolic risk factors and cardiovascular disease are highly prevalent conditions and will often coexist in an individual patient. Accordingly, we have reviewed the cardiometabolic consequences of hypothyroidism and intervention with thyroid hormone replacement. Main body: Numerous observational studies and meta-analyses have described multiple potentially adverse cardiometabolic consequences of hypothyroidism, including exacerbation of cardiovascular and metabolic risk factors (especially dyslipidaemia), functional impairment of the heart and vasculature (including accelerated atherosclerosis) and increased risk of advanced cardiovascular outcomes. LT4 usually improves cardiometabolic risk factors in people with hypothyroidism and some (but not all) studies have reported improved vascular and cardiac function in LT4-treated populations. Observational data have suggested the possibility of improved cardiometabolic outcomes with LT4 treatment, particularly in younger people with hypothyroidism, although data from randomised, controlled trials are needed here. Importantly, LT4 (with or without additional triiodothyronine) appears to be safe from a cardiovascular perspective, as long as overtreatment and iatrogenic thyrotoxicosis are avoided. Conclusions: Overall, the current evidence base supports intervention with LT4 to protect the cardiometabolic health of people with hypothyroidism who require thyroid hormone replacement, although more data on long-term clinical outcomes are needed.
- 20 May 2025
- Published by Springer Nature in Thyroid Research
- Vol. 18 (1) , 1-15
Open AccessHypothyroidism: playing the cardiometabolic risk concerto
Background: Thyroid hormones influence the function of essentially every system of the body, including the cardiovascular and metabolic system. Thyroid hormone replacement with levothyroxine (LT4) is the mainstay of pharmacological management for people with (especially clinically overt) hypothyroidism, and it is important to ensure the cardiovascular and metabolic safety of this treatment. This is especially so as in hypothyroidism, cardiometabolic risk factors and cardiovascular disease are highly prevalent conditions and will often coexist in an individual patient. Accordingly, we have reviewed the cardiometabolic consequences of hypothyroidism and intervention with thyroid hormone replacement. Main body: Numerous observational studies and meta-analyses have described multiple potentially adverse cardiometabolic consequences of hypothyroidism, including exacerbation of cardiovascular and metabolic risk factors (especially dyslipidaemia), functional impairment of the heart and vasculature (including accelerated atherosclerosis) and increased risk of advanced cardiovascular outcomes. LT4 usually improves cardiometabolic risk factors in people with hypothyroidism and some (but not all) studies have reported improved vascular and cardiac function in LT4-treated populations. Observational data have suggested the possibility of improved cardiometabolic outcomes with LT4 treatment, particularly in younger people with hypothyroidism, although data from randomised, controlled trials are needed here. Importantly, LT4 (with or without additional triiodothyronine) appears to be safe from a cardiovascular perspective, as long as overtreatment and iatrogenic thyrotoxicosis are avoided. Conclusions: Overall, the current evidence base supports intervention with LT4 to protect the cardiometabolic health of people with hypothyroidism who require thyroid hormone replacement, although more data on long-term clinical outcomes are needed.